Trending...
- Winners Announced for Asia Pacific Business Awards 2024-2025
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
~ A recent study presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition has found that patients with mantle cell lymphoma (MCL) who have no detectable cancer after initial therapy do not experience any survival benefit from undergoing a stem cell transplant compared to receiving maintenance therapy alone.
The trial, known as EA4151, was stopped early after an interim analysis was conducted when the study had followed patients for a median of 2.7 years. The results showed that patients who tested negative for minimal residual disease (MRD) with an ultra-high sensitivity blood test did not need to undergo a stem cell transplant or the high-dose chemotherapy regimen typically used to prepare for a transplant.
Lead author of the study, Dr. Timothy S. Fenske, stated that these findings suggest that physicians can feel comfortable omitting the transplant in MRD-negative patients. He also noted that in today's treatment landscape for MCL, good outcomes can be achieved without the high-dose chemotherapy and transplant. However, for patients who remain MRD-positive following induction therapy, a stem cell transplant may still be considered.
More on Wisconsin Eagle
MCL is a rare and aggressive blood cancer that primarily affects older adults. After initial chemotherapy, doctors often recommend a stem cell transplant to further reduce the level of residual lymphoma. However, this practice is based on studies conducted before newer and more effective treatments such as chemotherapy, immune therapy, and targeted therapies were available.
The trial enrolled 650 patients between 2017-2024 who were in their first remission after initial treatment for MCL. The participants had a median age of 60 years and were predominantly male and white. Each patient's remission status was assessed using various tests including PET/CT scans, bone marrow biopsies, and highly sensitive blood tests.
The patients were then divided into three groups based on their test results: MRD-negative (no evidence of cancer), MRD-positive (evidence of cancer in one or more cells per million), or MRD-indeterminate (testing incomplete or evidence of cancer in greater than zero but less than one cell per million).
Of the 516 patients who tested MRD-negative, they were randomly assigned to receive either a stem cell transplant and three years of maintenance rituximab or three years of maintenance rituximab alone. The remaining patients (MRD-positive and MRD-indeterminate) were assigned to receive a stem cell transplant and three years of maintenance rituximab.
More on Wisconsin Eagle
The interim analysis showed no significant difference in overall survival rates between the two groups in the MRD-negative category. With a median follow-up of 2.7 years, the overall survival rate was 82.1% for those who received a stem cell transplant and 82.7% for those who received maintenance therapy alone. The rate of survival without disease progression was also similar between the two groups.
Dr. Fenske emphasized that a stem cell transplant can be a difficult process for patients, with potential complications being especially risky for older individuals. He believes that if similar outcomes can be achieved without undergoing a transplant, it would be a significant step forward in improving treatment for MCL.
In conclusion, this study suggests that for MCL patients who test negative for minimal residual disease after initial therapy, undergoing a stem cell transplant may not provide any additional survival benefit compared to receiving maintenance therapy alone. This finding may lead to changes in current treatment recommendations and improve outcomes for these patients.
The trial, known as EA4151, was stopped early after an interim analysis was conducted when the study had followed patients for a median of 2.7 years. The results showed that patients who tested negative for minimal residual disease (MRD) with an ultra-high sensitivity blood test did not need to undergo a stem cell transplant or the high-dose chemotherapy regimen typically used to prepare for a transplant.
Lead author of the study, Dr. Timothy S. Fenske, stated that these findings suggest that physicians can feel comfortable omitting the transplant in MRD-negative patients. He also noted that in today's treatment landscape for MCL, good outcomes can be achieved without the high-dose chemotherapy and transplant. However, for patients who remain MRD-positive following induction therapy, a stem cell transplant may still be considered.
More on Wisconsin Eagle
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
MCL is a rare and aggressive blood cancer that primarily affects older adults. After initial chemotherapy, doctors often recommend a stem cell transplant to further reduce the level of residual lymphoma. However, this practice is based on studies conducted before newer and more effective treatments such as chemotherapy, immune therapy, and targeted therapies were available.
The trial enrolled 650 patients between 2017-2024 who were in their first remission after initial treatment for MCL. The participants had a median age of 60 years and were predominantly male and white. Each patient's remission status was assessed using various tests including PET/CT scans, bone marrow biopsies, and highly sensitive blood tests.
The patients were then divided into three groups based on their test results: MRD-negative (no evidence of cancer), MRD-positive (evidence of cancer in one or more cells per million), or MRD-indeterminate (testing incomplete or evidence of cancer in greater than zero but less than one cell per million).
Of the 516 patients who tested MRD-negative, they were randomly assigned to receive either a stem cell transplant and three years of maintenance rituximab or three years of maintenance rituximab alone. The remaining patients (MRD-positive and MRD-indeterminate) were assigned to receive a stem cell transplant and three years of maintenance rituximab.
More on Wisconsin Eagle
- Digital Watchdog Launches New myDW Cloud Services
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
The interim analysis showed no significant difference in overall survival rates between the two groups in the MRD-negative category. With a median follow-up of 2.7 years, the overall survival rate was 82.1% for those who received a stem cell transplant and 82.7% for those who received maintenance therapy alone. The rate of survival without disease progression was also similar between the two groups.
Dr. Fenske emphasized that a stem cell transplant can be a difficult process for patients, with potential complications being especially risky for older individuals. He believes that if similar outcomes can be achieved without undergoing a transplant, it would be a significant step forward in improving treatment for MCL.
In conclusion, this study suggests that for MCL patients who test negative for minimal residual disease after initial therapy, undergoing a stem cell transplant may not provide any additional survival benefit compared to receiving maintenance therapy alone. This finding may lead to changes in current treatment recommendations and improve outcomes for these patients.
Filed Under: Business
0 Comments
Latest on Wisconsin Eagle
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- Colbert Packaging Receives Safe Quality Food (SQF) Certification
- $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
- Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
- Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
- Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
- Winners Announced for Asia Pacific Business Awards 2024-2025
- Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence